A Phase 1 Investigator-and-subject Blind, Randomized, Placebo Controlled, Parallel Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Oral Doses Of Pf-06648671 On Aβ Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
At a glance
- Drugs PF 6648671 (Primary)
- Indications Unspecified
- Focus Pharmacodynamics
- Sponsors Pfizer
- 20 Jul 2017 Results of 3 phase 1 studies assessing plasma exposure and cerebrospinal fluid response relationship in healthy subjects, presented at the Alzheimer's Association International Conference 2017.
- 29 Mar 2016 Last checked against ClinicalTrials.gov record.
- 21 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.